Lost in Translation (LiT)

British Journal of Pharmacology

Volumn 171, Issue 9, 2014, Pages 2269-2290

  Dollery, Colin T ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

adherence; Big Data; breakthroughs; cost; ENCODE; golden years; GWAS; monoclonal antibodies; patients; regulation; roller coaster; safety

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRETROVIRUS AGENT; CHEMOKINE; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; MONOCLONAL ANTIBODY; PHOSPHOTRANSFERASE INHIBITOR;

BIOMICS; BLOOD BRAIN BARRIER; BLOOD PRESSURE REGULATION; BREAST CANCER; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG DESIGN; DRUG DIFFUSION; DRUG HALF LIFE; DRUG INDUSTRY; DRUG POTENCY; DRUG RESEARCH; DRUG SAFETY; EMPOWERMENT; EXPRESSED SEQUENCE TAG; GENETIC ASSOCIATION; GENOMICS; HIGH THROUGHPUT SCREENING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN GENOME PROJECT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTENSION; INDUSTRIALIZATION; MEDICAL RESEARCH; METABOLOMICS; MOLECULAR BIOLOGY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REVIEW; RNA SEQUENCE; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TRANSLATIONAL RESEARCH; ANIMAL; CARDIOVASCULAR DISEASES; DRUG DEVELOPMENT; PROCEDURES; STATISTICS; TRENDS;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DISCOVERY; HUMANS; STATISTICS AS TOPIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84898652025     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12580     Document Type: Review

References (141)

1. Adams MD, Kelley JM, Gocayne JD, Dubnick M, Polymeropoulos MH, Xiao H, et al. (1991). Complementary DNA sequencing: expressed sequence tags and human genome project. Science 252: 1651-1656. (Pubitemid 21917081)
2. Ahlquist RP, (1948). A study of the adrenotropic receptors. Am J Physiol 153: 586-600.
3. Apweiler R, Aslanidis C, Deufel T, Gerstner A, Hansen J, Hochstrasser D, et al. (2009). Approaching clinical proteomics: current state and future fields of application in fluid proteomics. Clin Chem Lab Med 47: 724-744.
4. Baigent C, Collins R, Appleby P, Parish S, Sleight P, Peto R, (1998). ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomised comparison of intravenous streptokinase, oral aspirin, both, or neither the ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Br Med J 316: 1337-1343. (Pubitemid 28195871)
5. Bandettini PA, (2012). Twenty years of functional MRI: the science and the stories. Neuroimage 62: 575-588.
6. Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B, (2007). Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem 389: 1017-1031. (Pubitemid 47482251)
7. Bartel DP, (2009). MicroRNAs: target recognition and regulatory functions. Cell 136: 215-233.
8. Bartolucci AA, Tendera M, Howard G, (2011). Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 107: 1796-1801.
9. Berinstein NL, Grillo-Lopez AJ, White CA, Bence-Bruckler I, Maloney D, Czuczman M, et al. (1998). Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 9: 995-1001. (Pubitemid 28496709)
10. Black J, (1996). A personal view of pharmacology. Annu Rev Pharmacol Toxicol 36: 1-33. (Pubitemid 26168692)
11. Blanas E, Carbone FR, Allison J, Miller JF, Heath WR, (2006). Cytokine storm in a phase 1 trial of the antiCD28 monoclonal antibodyTGN141. N Engl J Med 355: 1018-1028.
12. Blundell TL, Jhoti H, Abell C, (2002). High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 1: 45-54. (Pubitemid 37361403)
13. Bonislawski A, (2013) the unsteady march of cancer protein biomarkers into the clinic the Global Newsweekly of Proteomic Technology (May 10, 2013).
14. Brehm MA, Shultz LD, Greiner DL, (2010). Humanized mouse models to study human diseases. Curr Opin Endocrinol Diabetes Obes 17: 120-125.
15. Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, et al. (2010). Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. Landes Bioscience 2 (3): 233-255.
16. Buss NA, Henderson SJ, McFarlane M, Shenton JM, de Haan L, (2012). Monoclonal antibody therapeutics: history and future. Curr Opin Pharmacol 12: 615-622.
17. Chames P, Baty D, (2009). Bispecific antibodies for cancer therapy the light at the end of the tunnel? Landes Bioscience 1: 1-9.
18. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, et al. (2011). Carbamazepine-induced toxic effects and HLA-B 1502 screening in Taiwan. N Engl J Med 364: 1126-1133.
19. Choudhry NK, Winkelmayer WC, (2008). Medication adherence after myocardial infarction: a long way left to go. J Gen Intern Med 23: 216-218.
20. Clinton W, Blair T, (2000) the White House, Office of the Press Secretary. Available at: http://www.genome.gov/10001356 (accessed 24/2/2014).
21. Cote HCF, Brumme ZL, Craib KJP, Math M, Alexander CS, Wynhoven B, et al. (2002). Changes in mitochondrial DNA as a marker of nucleoside toxicity. N Engl J Med 346: 811-820. (Pubitemid 34984654)
22. Cui Y, Paules RS, (2010). Use of transcriptomics in understanding mechanisms of drug-induced toxicity. Pharmacogenomics 11: 573-585.
23. Dai L, Gao X, Guo Y, Xiao J, Zhang Z, (2012). Bioinformatics clouds for big data manipulation. Biol Direct 7: 43.
24. Daly AK, (2012). Genetic polymorphisms affecting drug metabolism: recent advances and clinical aspects. Adv Pharmacol 63: 137-167.
25. Davey RT, Bhat N, Yoder C, Chun TW, (1999). HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 96: 15109-15114. (Pubitemid 30019773)
26. De Clercq E, (2009). Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 33: 307-320.
27. Delaney M, (2006). History of HAART-the true story of how effective multi-drug therapy was developed for treatment of HIV disease. Retrovirology 3 (Suppl. 1): S6.
28. Department of Health (2006). Expert Group on Phase I Clinical Trials Final Report (Chaired by Professor Sir Gordon W. Duff). Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsPolicyAndGuidance/DH-063117 (accessed 24/2/2014).
29. Dieterle F, Sistare F, Goodsaid F, Papaluca M, Ozer JS, Webb CP, et al. (2010). Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium. Nat Biotechnol 28: 455-462.
30. Dollery CT, (2013). Intracellular drug concentrations. Clin Pharmacol Ther 93: 263-266.
31. Dorn GW, (2011). MicroRNAs in cardiac disease. Transl Res 157: 226-235.
32. Dostalek M, Gardner I, Gurbaxani BM, Rose RH, Chetty M, (2013). Pharmacokinetics, pharmacodynamics and physiologically based pharmacokinetic modelling of monoclonal antibodies. Clin Pharmacokinet 52: 83-124.
33. Doyle AE, (1991). Sir Horace Smirk pioneer in drug treatment of hypertension. Hypertension 17: 247-250.
34. Dunlop D, (1977). Problems of communication of a drug regulatory authority. Proc R Soc Med 70: 831-832. (Pubitemid 8244327)
35. Dusetzina SB, Higashi AS, Dorsey ER, Conti R, Huskamp HA, Zhu S, et al. (2012). Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care 50: 466-478.
36. Eastwood D, Findlay L, Poole S, Bird C, Wadhwa M, Moore M, et al. (2010). Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Brit J Pharmacol 161: 512-526.
37. Ecker JR, Bickmore WA, Barroso I, Pritchard JK, Gilad Y, Segal E, (2012). Genomics: ENCODE explained. Nature 489: 52-55.
38. Edmundson AB, Guddat LW, Andersen KN, (1993). Crystal structure of intact IgG antibodies. Immunomethods 3: 197-210.
39. Even-Desrumeaux K, Fourquet P, Secq V, Baty D, Chames P, (2012). Single-domain antibodies: a versatile and rich source of binders for breast cancer diagnostic approaches. Mol Biosyst 8: 2385-2394.
40. Food and Drug Administration (2012). FDA Guidance for Industry Drug Interaction Studies, Study Design, Data Analysis, Implications for Dosing, and Labelling Recommendations. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf (accessed 24/2/2014).
41. Food and Drug Administration (2013). Approved Risk Evaluation and Mitigation Strategies (REMS). Available at: http://www.fda.gov/drugs/drugsafety/ postmarketdrugsafetyinformationforpatientsandproviders/ucm111350.htm (accessed 24/2/2014).
42. Feldmann M, Maini RN, (2010). Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us. J Immunol 185: 791-794.
43. Gall A, Ferns B, Morris C, Watson S, Cotten M, Robinson M, et al. (2012). Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes. J Clin Microbiol 50: 3838-3844.
44. van der Geest RJ, Reiber JHC, (1999). Quantification in cardiac MRI. J Magn Reson Imaging 10: 602-608. (Pubitemid 29519761)
45. Gerstein M, (2012). Genomics: ENCODE leads the way on big data. Nature 489: 208.
46. Graur D, Zheng Y, Price N, Azevedo RB, Zufall RA, Elhaik E, (2013). On the immortality of television sets: 'function' in the human genome according to the evolution-free gospel of ENCODE. Genome Biol Evol 5: 578-590.
47. Grenard JL, Munjas BA, Adams JL, Suttorp M, Maglione M, McGlynn EA, et al. (2011). Depression and medication adherence in the treatment of chronic diseases in the United States: a meta-analysis. J Gen Intern Med 26: 1175-1182.
48. Hajduk PJ, Greer J, (2007). Decade of fragment-based drug design: strategic advances and lessons learned. Nat Rev Drug Discov 6: 211-219. (Pubitemid 46344625)
49. Hanash LAS, Taguchi A, (2010) the grand challenge to decipher the cancer proteome. Nat Rev Cancer 10: 652-660.
50. Harvard Medical School (2011). Initiative in Systems Pharmacology. Available at: http://isp.hms.harvard.edu/ (accessed 24/2/2014).
51. Henn MR, Boutwell CL, Charlebois P, Lennon NJ, Power KA, Macalalad AR, et al. (2012). Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog 8: e1002529.
52. Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R, (1989). Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 80: 749-756. (Pubitemid 19261621)
53. Hitchings GH, (2003). Selective inhibitors of dihydrofolate reductase. Angew Chem Int Ed Engl 28: 879-885.
54. Ho JE, Larson MG, Vasan RS, Ghorbani A, Cheng S, Rhee EP, et al. (2013). Metabolite profiles during oral glucose challenge. Diabetes 62: 2689-2698.
55. Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM, (2003). Domain antibodies: proteins for therapy. Trends Biotechnol 21: 484-490. (Pubitemid 37324200)
56. Hudis CA, (2007). Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 357: 39-51. (Pubitemid 47026733)
57. Human Metabolome Database. Strengthening-big-data-in-the-pharmaceutical- industry. Available at: http://www.hmdb.ca/ (accessed 25/2/2014).
58. Hunter T, (2009). Tyrosine phosphorylation: thirty years and counting. Curr Opin Cell Biol 21: 141-146.
59. Ioannidis JPA, (2005). Why most published research findings are false. PLoS Med 2: e124.
60. Ioannidis JPA, (2013). Informed consent, big data, and the oxymoron of research that is not research. Am J Bioeth 13: 40-42.
61. Ito R, Takahashi T, Katano I, Ito M, (2012). Current advances in humanized mouse models. Cell & Mol Immunol 9: 208-214.
62. Johnson KA, Fox NC, Sperling RA, Klunk WE, (2012). Brain imaging in Alzheimer disease. Cold Spring Harbor Perspect Med 2: a006213.
63. Junttila TT, Li G, Parsons K, Phillips GL, Siwkowski MX, (2011). Trastuzumab-DM1 (TiDM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatanib insensitive breast cancer. Breast Cancer Res Treat 128: 347-356.
64. Kaddurah-Daouk R, Kristal BS, Weinshilboum RM, (2008). Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol 48: 653-683. (Pubitemid 351738167)
65. Kasinsk AL, Slack FJ, (2011). MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 11: 849-864.
66. Katlama C, Deeks SG, Autran B, Martinez-Picado J, van Lunzen J, Rouzioux C, et al. (2013). Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet 381: 2109-2117.
67. Kishimoto T, (2010). IL-6: from its discovery to clinical applications. Int Immunol 22: 347-352.
68. Koeller KM, Wong CH, (2001). Enzymes for chemical synthesis. Nature 409: 232-240. (Pubitemid 32146169)
69. Kohler G, Milstein C, (1975). Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
70. Kontermann RE, (2012). Dual targeting strategies with bispecific antibodies. Landes Bioscience 4: 182-197.
71. Kwee TC, Torigian DA, Alavi A, (2013). Overview of positron emission tomography, hybrid positron emission tomography instrumentation, and positron emission tomography quantification. J Thorac Imaging 28: 4-10.
72. Lancelot S, Zimmer L, (2010). Small-animal positron emission tomography as a tool for neuropharmacology. Trends Pharmacol Sci 3: 411-417.
73. Leeson PD, Springthorpe B, (2007) the influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov 6: 881-890. (Pubitemid 350042396)
74. Legrand N, Ploss A, Balling R, Becker PD, Borsotti C, Brezillon N, et al. (2009). Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe 6: 5-9.
75. Lenz W, (1988). A short history of thalidomide embryopathy. Teratology 38: 203-215.
76. Ley-Zaporozhan JS, Ley S, Kauczor H-U, (2008). Morphological and functional imaging in COPD with CT and MRI: present and future. Eur Radiol 18: 510-521. (Pubitemid 351248182)
77. Liao JJ, (2007). Molecular recognition of protein kinase binding pockets to design potent and selective kinase inhibitors. J Med Chem 50: 409-424. (Pubitemid 46239775)
78. Lipinski CA, (2004). Lead- and drug-like compounds: the rule-of-five revolution. Drug Discov Today: Technol 1: 337-341. (Pubitemid 40186335)
79. Lonberg N, Taylor LD, Harding FA, Trounstine M, Higgins KM, Schramm SR, et al. (1994). Antigen-specific human antibodies from mice comprising four distinct genetic modifications. Nature 368: 856-859. (Pubitemid 24137750)
80. Maher B, (2012). ENCODE: The human encyclopaedia. Nature 489: 46-48.
81. Malboeuf CM, Xiao Y, Charlebois P, Qu J, Berlin AM, Casali M, et al. (2012). Complete viral RNA genome sequencing of ultra-low copy samples by sequence-independent amplification. Nucleic Acids Res 41: e13.
82. Mangravite LM, Engelhardt BE, Medina MW, Smith JD, Brown CD, et al. (2013). A statin-dependent QTL for GATM expression is associated with statin-induced myopathy. Nature 501: 377-380.
83. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S, (2002) the protein kinase complement of the human genome. Science 298: 1912-1934. (Pubitemid 35425239)
84. Martinez Molina D, Jafari R, Ignatushchenko M, Seki T, Larsson EA, Chen D, et al. (2013). Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341: 84-87.
85. Marx V, (2013). Biology: the big challenges of big data. Nature 498: 255-260.
86. Matthews PM, Rabiner EA, Passchier J, Gunn RN, (2012). Positron emission tomography molecular imaging for drug development. Br J Clin Pharmacol 73: 175-186.
87. McCafferty J, Griffiths AD, Winter G, Chiswell DJ, (1990). Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348: 552-554. (Pubitemid 120015109)
88. McShane LM, Margaret M, Cavenagh MM, Lively TG, Eberhard DA, Bigbee WL, (2013). Criteria for the use of omics-based predictors in clinical trials. Nature 5012: 317-320.
89. Medical Research Council Working Party (1985). MRC trial of treatment of mild hypertension:principal results. Br Med J 291: 97-104.
90. Mestas J, Hughes CCW, (2004). Of mice and not men: differences between mouse and human immunology. J Immunol 172: 2731-2738. (Pubitemid 38263654)
91. Moore JB, Weeks ME, (2011). Proteomics and systems biology: current and future applications in the nutritional sciences. Adv Nutr 2: 355-364.
92. Morabito F, Gentile M, Mazzone C, Rossi D, Bringen F, Ria R, et al. (2011). Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-melphalan-prednisone (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. Blood 118: 5759-5766.
93. Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS, Wegner CD, et al. (2012). Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving phase II survival. Drug Discov Today 17: 419-424.
94. Mukherjee S, (2011) The Emperor of All Maladies: A Biography of Cancer. Simon & Schuster: New York.
95. Muller BA, (2009). Imatinib and its successors-how modern chemistry has changed drug development. Curr Pharm Des 15: 120-133.
96. National Cancer Institute (2013). Office of Cancer Clinical Proteomics Research/CPTAC Data Portal Overview (2011-present). Available at: http://proteomics.cancer.gov (accessed 3/2014).
97. Nature Editorial (2005). 'Proteomics', new order. Nature 437: 169-170.
98. Nature/omics (2010). Home page. Available at: http://www.nature.com/ omics/index.html (accessed 24/2/2014).
99. Nelson MR, Reid CM, Ryan P, Willson K, Yelland L, (2006). Self-reported adherence with medication and cardiovascular disease outcomes in the Second Australian National Blood Pressure Study (ANBP2). Med J Aust 185: 487-489. (Pubitemid 44756209)
100. Neuburger J, Kenna JG, (1987). Halothane hepatitis: a model of immune mediated hepatitis. Clin Sci 72: 263-270. (Pubitemid 17012600)
101. Okamoto H, Kobayashi A, (2011). Tyrosine kinases in rheumatoid arthritis. J Inflamm 8: 1-7.
102. O'Shea JJ, Murray PJ, (2008). Cytokine signaling modules in inflammatory responses. Immunity 28: 477-487. (Pubitemid 351467044)
103. Partridge AH, Wang PS, Winer EP, Avorn J, (2003). Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21: 602-606. (Pubitemid 46621892)
104. Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, et al. (1980). Low dose aspirin and inhibition of thromboxane B2 production. Thromb Res 17: 317-327.
105. Patti GJ, Yanes O, Siuzdak G, (2012). Metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol 13: 263-269.
106. Pedersen TR, Olsson AG, Faergeman O, Kjekhus J, Wedel H, Berg K, et al. (1998). Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study (4S). Circulation 97: 1453-1460. (Pubitemid 28191300)
107. Prinz F, Schlange T, Asadullah K, (2011). Believe it or not: how much can we rely on published data on potential drug targets. Nat Rev Drug Discov 10: 712.
108. Ratajczak MZ, Zuba-Surm E, Kucia M, Reca R, Wojakowsk W, Ratajcza J, (2006) the pleiotropic effects of the SDF-1-CXCR4 axis in organogenesis, regeneration and tumorigenesis. Leukemia 20: 1915-1924. (Pubitemid 44614878)
109. Rifai N, Gillette MA, Carr SA, (2006). Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 24: 971-983. (Pubitemid 44215392)
110. Romaine SPR, Bailey KM, Hall AS, Balmforth AJ, (2010) the influence of SLCO1B1 (OATP1B1) gene polymorphisms on response to statin therapy. Pharmacogenomics J 10: 1-11.
111. Ryan R, Santesso N, Hill S, Lowe D, Kaufman C, Grimshaw J, (2011). Consumer-oriented interventions for evidence-based prescribing and medicines use: an overview of systematic reviews. Cochrane Database Syst Rev (5): CD007768.
112. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. (2014). Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer's Disease. N Engl J Med 370: 322-333.
113. Schnieders MJ, Kaoud TS, Yan C, Dalby KN, Ren P, (2012). Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases. Curr Pharm Des 18: 1173-1185.
114. Schwartz PA, Murray BW, (2011). Protein kinase biochemistry and drug discovery. Bioorg Chem 39: 192-210.
115. Searfoss GH, Ryan TP, Jolly RA, (2005) the role of transcriptome analysis in pre-clinical toxicology. Curr Mol Med 5: 53-64. (Pubitemid 40352874)
116. Shen Y, Zhang R, Moore RJ, Kim J, Metz TO, Hixson KK, et al. (2005). Automated 20 kpsi RPLC-MS and MS/MS with chromatographic peak capacities of 1000-1500 and capabilities in proteomics and metabolomics. Anal Chem 77: 3090-3100. (Pubitemid 40695464)
117. Shultz LD, Ishikawa F, Greiner DL, (2007). Humanized mice in translational biomedical research. Nat Rev Immunol 7: 118-130. (Pubitemid 46174859)
118. Sivaraman A, Leach JK, Townsend S, Iida T, Hogan BJ, Stolz DB, et al. (2005). A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr Drug Metab 6: 569-591. (Pubitemid 41672495)
119. Spraggs CF, Parham LR, Hunt CM, Dollery CT, (2012). Lapatinib-induced liver injury characterized by class II HLA and Gilbert's syndrome genotypes. Clin Pharmacol Ther 91: 647-652.
120. Sreekuma A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. (2009). Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 12: 910-914.
121. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner FD, et al. (2006). Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412. N Engl J Med 355: 1018-1028. (Pubitemid 44343545)
122. Temple R, (2006). Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 15: 241-243.
123. Tesch C, Amur S, Schouboe JT, Siegel JN, Lesko LJ, Bai JP, (2010). Successes achieved and challenges ahead in translating biomarkers into clinical applications. AAPS J 12: 243-252.
124. Tetko IV, Gasteiger J, Todeschini R, Mauri A, Livingstone DE, Palyulin VA, et al. (2005). Virtual computational chemistry laboratory-design and description. J Comput Aided Mol Des 19: 453-463. (Pubitemid 41613292)
125. The Wellcome Trust (2009). Coming up trumps: Genome-wide association studies. Available at: http://www.wellcome.ac.uk/about-us/publications/annual- review/wtdv027330.htm (accessed 24/2/2014).
126. Tobert J, (2003). Lovastatin and beyond: the history of HMG Co-A reductase inhibitors. Nat Rev Drug Discov 2: 517-526. (Pubitemid 37361744)
127. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP, (2008). Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther 117: 244-279.
128. Turer AT, Stevens RD, Bain JR, Muehlbauer MJ, van der Westhuizen J, Mathew JP, et al. (2009). Metabolomic profiling reveals distinct patterns of myocardial substrate use in humans with coronary artery disease or left ventricular dysfunction during surgical ischemia/reperfusion. Circulation 19: 1736-1746.
129. Van Gestel S, Schuermans V, (1986). Thirty-three years of drug discovery and research with Dr Paul Janssen. Drug Dev Res 8: 1-13. (Pubitemid 16078118)
130. Vane JR, Flower RJ, Botting RM, (1990). History of aspirin and its mechanism of action. Stroke; a Journal of Cerebral Circulation 21 (Suppl 12): IV12-IV23.
131. Wang XW, Heegaard NH, Orum H, (2012). MicroRNAs in liver disease. Gastroenterology 142: 1431-1443.
132. Wang Z, Gerstein M, Snyder M, (2009). RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 10: 57-63.
133. Wei R, (2011). Metabolomics and its practical value in pharmaceutical industry. Curr Drug Metab 12: 345-358.
134. Weiss HJ, Aledort LM, Kochwa S, (1968) the effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 47: 2169-2180.
135. Whitesides GM, (2006) the origins and the future of microfluidics. Nature 442: 368-373. (Pubitemid 44264779)
136. Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE, et al. (2004). Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol 114: 1288-1293. (Pubitemid 39575880)
137. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, et al. (2010). Can animal models of disease reliably inform human studies? PLoS Med 7: 3-e1000245.
138. Wright P, (1975). Untoward effects associated with practolol administration: oculomucocutaneous syndrome. Br Med J 1975: 595-598.
139. Wyss (2013). Wyss Institute for Biologically Inspired Engineering. Available at: http://integralife.com/ (accessed 25/2/2014).
140. Yin W, Carballo-J E, McLaren DG, Mendoza KG, Geoghagen NS, McNamara LN, et al. (2012). Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res 53: 51-65.
141. Zerhouni EA, (2005). Translational and clinical science-time for a new vision. N Engl J Med 353: 1621-1623. (Pubitemid 41434645)